Skip to main content
. Author manuscript; available in PMC: 2011 Feb 15.
Published in final edited form as: Prostaglandins Other Lipid Mediat. 2010 Dec 15;94(1-2):34–43. doi: 10.1016/j.prostaglandins.2010.12.002

Figure 1.

Figure 1

Effects of ECs and hydrolysis inhibitors on prostate carcinoma cell proliferation. (A) Effects of AEA (0.1, 1.0 and 10 μM), SR141716A (SR-1, a selective CB1R antagonist) and SR144528 (SR-2, a selective CB2R antagonist) on proliferation (thymidine incorporation assay) of PC-3 cells. Values are mean ± SEM (n = 12). *, significantly lower than the control cells with p < 0.05; #, significantly higher than AEA-treated cells. (B) Effects of 2-AG (0.1, 1.0 and 10 μM) on proliferation (thymidine incorporation assay) of PC-3 cells. Values are mean ± SEM (n = 12). #, significantly higher than the control cells with p < 0.05. (C) Effects of hydrolase inhibitors (OTFP and DAK, 10 μM) and a combination of OTFP or DAK and 2-AG (10 μM) on proliferation (thymidine incorporation assay) of PC-3 cells. Values are mean ± SEM (n = 6-12). *, significantly lower than the control cells with p < 0.05; #, significantly higher than the control cells with p < 0.05; **, significantly lower than the OTFP-treated or DAK-treated cells with p < 0.05.

HHS Vulnerability Disclosure